Welcome to our dedicated page for Nucana SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NuCana plc (NCNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. NuCana files annual reports on Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934, which together give investors detailed insight into its clinical-stage oncology business, financial position, and capital markets activity.
Through these filings, NuCana reports unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and information on equity financings, warrant issuances and cancellations, and at-the-market offering activity. Form 6-K submissions also include press releases on quarterly financial results, clinical data for NUC-7738 and NUC-3373, Nasdaq listing matters, ADS ratio changes, and corporate governance updates such as leadership transitions and board resignations.
For investors analyzing NuCana’s cancer drug development programs, the filings complement press releases by documenting how clinical progress, such as the NuTide:701 and NuTide:303 studies, is reflected in research and development spending, cash resources, and risk disclosures. While NuCana’s filings do not include U.S. domestic forms like 10-K or 10-Q, the Form 20-F and associated 6-K exhibits serve similar roles in outlining key risks, forward-looking statements, and the company’s dependence on external capital to fund operations.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR and can be paired with AI-powered summaries that highlight important sections, such as liquidity discussions, changes in capital structure, and descriptions of clinical milestones. Users can quickly locate specific 6-K reports tied to financial results, Nasdaq compliance updates, patent announcements, or other material events, and review how NuCana describes its ProTide technology, oncology pipeline, and anticipated cash runway within its official regulatory communications.
NuCana plc reports that Hugh S. Griffith has returned to his role as Chief Executive Officer and principal executive officer, effective December 15, 2025.
During his health-related leave, Executive Chairman Andrew Kay had been acting as the company’s principal executive officer; upon Mr. Griffith’s return, Mr. Kay resumed his prior position as Chairman of the Board. The update is also stated to be incorporated by reference into NuCana’s existing shelf and equity compensation registration statements on Form F-3 and Form S-8.
NuCana plc furnished a Form 6-K noting it issued a press release announcing third quarter 2025 financial results and provided accompanying materials. The filing includes unaudited condensed consolidated financial statements as of September 30, 2025 (Exhibit 99.1), Management’s Discussion and Analysis for the three and nine months ended September 30, 2025 and 2024 (Exhibit 99.2), and the November 13, 2025 press release (Exhibit 99.3).
Exhibits 99.1 and 99.2 are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-281576) and Form S-8 (File Nos. 333-223476 and 333-248135). Exhibit 99.3 is being furnished and is not deemed filed. The Company also disclosed that, effective October 21, 2025, Bali Muralidhar, M.D., Ph.D. resigned from the Board and all committees; the resignation was not the result of any dispute regarding operations, policies, or practices.
NuCana plc (NCNA) reported that the China National Intellectual Property Administration issued a new patent covering NUC‑7738’s composition of matter. The update was communicated via a press release attached as Exhibit 99.1.
The information is incorporated by reference into the company’s registration statements on Form F‑3 (File No. 333-281576) and Form S‑8 (File Nos. 333-223476, 333-248135). The press release is being furnished, not filed, under the Exchange Act.
NuCana plc furnished a Form 6-K announcing it issued a press release about new research presented at ESMO 2025. The presentation covers a model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma.
The press release is attached as Exhibit 99.1 and is incorporated by reference. The information in Exhibit 99.1 is being furnished and not deemed filed under the Exchange Act.
NuCana plc reported an update via Form 6-K, stating that on October 14, 2025 it announced the publication of new data from the NuTide:303 clinical study evaluating NUC-3373 on medRxiv, alongside complementary preclinical findings published in the peer‑reviewed journal PLOS ONE.
The company furnished a press release as Exhibit 99.1. The information is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except by specific reference.
NuCana plc has confirmed that it is now in compliance with all applicable continued listing criteria of The Nasdaq Capital Market. This follows earlier notices from Nasdaq that the bid price of NuCana’s American Depositary Shares had fallen below the minimum bid price requirement, and had also closed below $0.10 per share for 10 consecutive trading days, which put the shares at risk of delisting.
The company presented a plan to regain compliance at a Nasdaq Hearings Panel meeting on August 21, 2025. On September 4, 2025, Nasdaq’s Office of the General Counsel notified NuCana that it is in compliance with Nasdaq’s listing rules, meaning its ADSs can continue trading on The Nasdaq Capital Market under current criteria.
NuCana plc reported that it will give a presentation at the European Society for Medical Oncology (ESMO) Congress 2025, which takes place October 17-21, 2025 in Berlin, Germany. This update comes via a company press release dated September 3, 2025, which is included as an exhibit to the report. The content of the press release is furnished for informational purposes and is not treated as filed under U.S. securities law unless specifically incorporated into other company disclosures.
Key event: On 21 Jul 2025 NuCana plc (NCNA) filed a Form 6-K reporting the cancellation of all outstanding Series A American Depositary Share purchase warrants. The move follows completion of a strategic at-the-market (ATM) execution.
The filing contains no financial statements, earnings metrics or additional material events. A press release with further details is provided as Exhibit 99.1 and incorporated by reference. The report was signed by Interim CFO Ian Webster.
- Form type: 6-K (foreign issuer current report)
- Purpose: disclose warrant cancellation
- Exhibit: 99.1 – press release dated 21 Jul 2025
No additional information on revenue, guidance, debt, litigation or operational performance was disclosed.
FAQ
What is the current stock price of Nucana (NCNA)?
What is the market cap of Nucana (NCNA)?
